UPC at four months old - a review
The UPC is now four months old and the Court of First Instance is..
Mewburn Ellis praised for achievements in sustainability
EcoVadis ratings highlight environmental policies and sustainable..
Come and join us for a ‘Celebration of all things Singapore’
We are excited to be in Singapore for INTA 2023 and very much hope..
Opting out from the UPC – when to opt-out a pending European patent application
From 1 March 2023, when the Unified Patent Court (UPC) sunrise period..
Robert Watson elected President of FICPI’s Study and Work Committee
Partner Robert Watson was elected President of FICPI’s Study and Work..
Mewburn Ellis: top tier firm Legal 500 2022
Mewburn Ellis board signs IP Inclusive Leaders’ Pledge
Mewburn Ellis’ nine board members are proud to be amongst dozens of..
Diversity & inclusion is high on our agenda
Diversity & inclusion is high on the agenda for Mewburn Ellis, it’s..
Singapore's biotech breakthrough
From the far east to the east coast of America, the world is taking..
Changes to our correspondence address
In response to the current situation in London due to Coronavirus..
Coronavirus (COVID-19) Update
Updated: 2pm Sunday 1st November 2020
Mewburn Ellis took the..
Oppositions & Appeals: we opened the door for different types of data to support a medical use
Case 4 - T 801/06 (EPO Board of Appeal, 4 March 2009)
Now cited in..
Meet the team: Richard Clegg, Partner, European Patent Attorney, Patent Attorney Litigator
As part of our 'meet the team' series, we talk to Richard Clegg about..
Challenges Post Selex
Twenty-five years ago Tuerk and Gold reported the Selex method. Being..
Clovis Oncology success in European Opposition Proceedings related to Rubraca®
Clovis Oncology has announced that the European Patent Office (EPO)..
Morphosis: creating and nurturing biotech start-ups in Singapore
We understand that early-stage biotech companies do not have it easy...